euract® cream versus placebo in the relief of neuropathic lower back pai

Completed

• Conditions: Dorsalgia; europathic lower back pain; Musculoskeletal Diseases

• Registration Number: ISRCTN38072382
• Lead Sponsor: Origin Biomed, Inc (Canada)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-07-14
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. At least 21 years old
2. Diagnosed with neuropathic lower back pain for at least 3 months
3. Pain at or more than level 5 but no more than 9 on a 0-10 scale
4. Score at least 6 of 10 on the modified DN4 questionnaire
5. Normal cognitive and communication skills

Exclusion Criteria

1. Pregnant, breastfeeding or planning on becoming pregnant in the next 3 months
2. Previous adverse reaction to use of topical analgesic
3. Current use of topical analgesic on lower back area
4. Evidence of other types of pain as, or more severe, than the pain under study
5. Diagnosis of psychological disorder requiring treatment
6. History of eczema/atopy/anaphylaxis or unusual skin reactions
7. Self reported sensitivity to perfumes, essential oils, odors
8. Changes to current pain management regime within the previous 30 days prior to start of study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evel of pain on a 0-10 visual scale, measured 30 minutes before and after the application of of the treatment, and every hour thereafter for 8 hours.

Secondary Outcome Measures

Name	Time	Method
Duration of pain reduction